Viyash Scientific appoints Dr. Nagineni as SVP HR amid leadership change

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Viyash Scientific Limited appointed Dr. Mallikharjuna Rao Nagineni as SVP HR effective October 20, 2026
  • Mr. Prasad Lad retired from his role as VP HR & Administration on the same date
  • Dr. Nagineni has over 25 years of experience including stints at Mylan and Mahindra & Mahindra
  • The appointment was approved by the Board via circular resolution on October 20, 2026
powered bylight_fuzz_icon
54037051

*this image is generated using AI for illustrative purposes only.

Viyash Scientific Limited appointed Dr. Mallikharjuna Rao Nagineni as Senior Vice President, Human Resources, effective October 20, 2026. This appointment marks a transition in the company's senior management personnel (SMP), coinciding with the retirement of the previous incumbent.

The Board of Directors approved the appointment based on the recommendation of the Nomination and Remuneration Committee. The decision was formalized through a circular resolution passed on October 20, 2026. Concurrently, Mr. Prasad Lad, Vice President - HR & Administration, ceased to be a Senior Management Personnel due to his forthcoming retirement.

Profile of new appointee

Dr. Mallikharjuna Rao Nagineni brings over 25 years of experience in strategic human resource management, industrial relations, organizational development, talent management, and employee engagement. His career includes leadership roles at prominent organizations such as Mylan Laboratories Limited, Mahindra & Mahindra Limited, Kewalram Chanrai Group, and Biological E. Limited.

He holds a Ph.D. in HR for Competency Development and Strategic Human Resources from Berhampur University, along with a Master of Law from Annamalai University. Additionally, he possesses a Master of Industrial Relations & Personnel Management and an MBA from Nagpur University. His expertise spans HR transformation, mergers and acquisitions, workforce integration, and people strategy across domestic and international operations.

Transition details

The change in senior management was intimated to BSE Limited and National Stock Exchange of India Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The following table summarizes the key details of the leadership transition:

Particulars Incoming Personnel Outgoing Personnel
Name Dr. Mallikharjuna Rao Nagineni Mr. Prasad Lad
Designation Senior Vice President, Human Resources Vice President, HR & Administration
Reason for Change Appointment Cessation due to retirement
Effective Date October 20, 2026 October 20, 2026

This leadership update ensures continuity in the human resources function, leveraging Dr. Nagineni's extensive background in industrial relations and organizational restructuring to support the company's operational goals.

Historical Stock Returns for Viyash Scientific

1 Day5 Days1 Month6 Months1 Year5 Years
-2.16%-5.53%-7.43%+6.18%+2.77%0.0%

How might Dr. Nagineni's specific experience in M&A workforce integration influence Viyash Scientific's future acquisition strategy?

What immediate changes to employee engagement programs or compensation structures can be expected under the new HR leadership?

Will the transition from Mr. Lad to Dr. Nagineni impact Viyash Scientific's existing industrial relations agreements or labor negotiations?

Viyash Scientific completes acquisition of BioForLife Italia

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • Viyash Scientific's subsidiary Alivira Animal Health acquired 100% of BioForLife Italia S.r.l.
  • Base purchase consideration paid on closing is EUR 15.0 million
  • Deferred consideration of EUR 1.976 million payable subject to adjustments
  • Acquisition completed on October 1, 2026, making BFL Italy a step-down subsidiary
powered bylight_fuzz_icon
52407749

*this image is generated using AI for illustrative purposes only.

Viyash Scientific Limited announced the completion of its step-down subsidiary's acquisition of 100% share capital in BioForLife Italia S.r.l. on October 1, 2026. The transaction expands the company's animal health footprint in Europe through its Irish subsidiary, Alivira Animal Health Limited.

Alivira Animal Health Limited, a wholly owned subsidiary of Viyash, executed the deal pursuant to a Sale and Purchase Agreement dated July 21, 2026. Consequently, BioForLife Italia S.r.l., based in Milan, Italy, has become a step-down wholly owned subsidiary of Viyash Scientific with effect from October 1, 2026.

Transaction Consideration Structure

The financial terms of the acquisition involve a split payment structure comprising an upfront base consideration and a deferred component. The total value is contingent on the net financial position of the target entity as calculated at specific intervals.

Component Amount (EUR) Status
Base purchase consideration 15.0 million Paid on closing
Deferred consideration 1.976 million Payable post-adjustments

The deferred portion is subject to necessary adjustments based on the computation of the net financial position as on the Closing Date, October 1, 2026, in accordance with the SPA terms.

Regulatory and Operational Updates

This completion follows earlier disclosures made by the company on June 8, 2026, July 21, 2026, and September 8, 2026. The transaction was intimated to BSE and NSE under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

As part of the closing procedures under the SPA, representatives from Alivira Animal Health Limited have been appointed to the Board of Directors of BioForLife Italia S.r.l. The company stated that the transaction stands consummated and closed in accordance with all previously disclosed terms and conditions.

Historical Stock Returns for Viyash Scientific

1 Day5 Days1 Month6 Months1 Year5 Years
-2.16%-5.53%-7.43%+6.18%+2.77%0.0%

How will the integration of BioForLife Italia's product portfolio impact Viyash Scientific's revenue mix in the European animal health segment over the next fiscal year?

What specific operational synergies or cost-saving measures is management targeting through the new board representation at BioForLife Italia?

How might the deferred consideration adjustments based on the net financial position affect Viyash's short-term cash flow projections for FY2027?

More News on Viyash Scientific

1 Year Returns:+2.77%